Pfizer Inc. $PFE Shares Acquired by Samalin Investment Counsel LLC

Samalin Investment Counsel LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 16.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 29,617 shares of the biopharmaceutical company’s stock after acquiring an additional 4,199 shares during the period. Samalin Investment Counsel LLC’s holdings in Pfizer were worth $751,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of PFE. William B. Walkup & Associates Inc. increased its position in shares of Pfizer by 1.2% during the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock worth $1,044,000 after purchasing an additional 454 shares during the last quarter. Members Trust Co raised its holdings in shares of Pfizer by 2.1% during the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 467 shares in the last quarter. Sutton Place Investors LLC increased its holdings in Pfizer by 5.6% in the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock worth $224,000 after purchasing an additional 472 shares in the last quarter. Bellevue Group AG increased its stake in shares of Pfizer by 0.3% in the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company’s stock valued at $3,756,000 after buying an additional 485 shares during the period. Finally, MSH Capital Advisors LLC grew its stake in Pfizer by 1.4% during the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company’s stock worth $876,000 after purchasing an additional 485 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 2.8%

Shares of Pfizer stock opened at $25.15 on Tuesday. The firm has a market cap of $142.99 billion, a price-to-earnings ratio of 13.38, a PEG ratio of 0.92 and a beta of 0.52. The business has a 50-day moving average price of $24.72 and a 200-day moving average price of $24.39. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the business posted $0.60 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Analysts Set New Price Targets

A number of brokerages recently commented on PFE. Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, May 21st. Berenberg Bank reduced their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. HSBC dropped their price objective on Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research note on Monday, May 19th. Finally, Morgan Stanley lifted their price target on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.